$CING
Cingulate Inc Stock $cing

$cing Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000149315223007252 Filed on March 10, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.721M	$2.543M	$8.506M
YoY Change	-23.39%	83.75%	-30.67%
% of Gross Profit
Research & Development	$2.129M	$1.932M	$8.995M
YoY Change	-22.94%	52.94%	6.95%
% of Gross Profit
Depreciation & Amortization	$100.6K	$89.72K	$394.0K
YoY Change	-0.79%	-74.87%	-44.37%
% of Gross Profit
Operating Expenses	$2.129M	$4.475M	$8.995M
YoY Change	-57.51%	69.05%	-56.5%
Operating Profit	-$3.850M		-$17.50M
YoY Change	-23.14%		-15.37%
Interest Expense	$187.5K	-$130.0K	$292.3K
YoY Change	3116.12%	1869.7%	-1055.67%
% of Operating Profit
Other Income/Expense, Net	-$154.9K		-$174.5K
YoY Change	-2755.44%		470.44%
Pretax Income	-$4.005M	-$4.605M	-$17.68M
YoY Change	-19.96%	73.53%	-14.65%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$4.005M	-$4.605M	-$17.68M
YoY Change	-19.96%	73.53%	-14.65%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.35		-$1.56
Diluted Earnings Per Share	-$0.35	-$0.41	-$1.56
COMMON SHARES
Basic Shares Outstanding	11.31M shares	11.31M shares	11.31M shares
Diluted Shares Outstanding	565.5K shares		602.3K shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.739M	$5.356M	$5.356M
YoY Change	-86.22%	-67.53%	-67.53%
Cash & Equivalents	$1.739M	$5.356M	$5.356M
Short-Term Investments		$0.00	$0.00
Other Short-Term Assets	$1.983M	$2.279M	$2.279M
YoY Change	51.68%	34.19%	34.19%
Inventory
Prepaid Expenses	$1.983M	$2.279M
Receivables	$31.95K	$234.4K	$234.4K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$3.753M	$7.870M	$7.870M
YoY Change	-74.25%	-58.32%	-58.32%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.841M	$2.905M	$3.535M
YoY Change	-26.37%	-7.65%	-11.7%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$3.410M	$3.535M	$3.535M
YoY Change	-11.65%	-11.7%	-11.7%
TOTAL ASSETS
Total Short-Term Assets	$3.753M	$7.870M	$7.870M
Total Long-Term Assets	$3.410M	$3.535M	$3.535M
Total Assets	$7.163M	$11.41M	$11.41M
YoY Change	-61.14%	-50.17%	-50.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$599.0K	$762.4K	$762.4K
YoY Change	7.68%	188.02%	188.02%
Accrued Expenses	$699.2K	$894.6K	$1.234M
YoY Change	-34.0%	48.78%	37.63%
Deferred Revenue
YoY Change
Short-Term Debt	$5.000M	$5.000M	$5.000M
YoY Change
Long-Term Debt Due	$16.30K	$16.05K	$16.05K
YoY Change	6.26%	6.29%	6.29%
Total Short-Term Liabilities	$6.659M	$7.013M	$7.013M
YoY Change	308.26%	495.98%	495.98%
LONG-TERM LIABILITIES
Long-Term Debt	$17.32K	$21.49K	$21.49K
YoY Change	-48.47%	-42.74%	-42.74%
Other Long-Term Liabilities	$405.5K	$488.8K	$488.8K
YoY Change	-45.9%		-41.01%
Total Long-Term Liabilities	$422.8K	$510.2K	$510.2K
YoY Change	-46.01%		-41.08%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.659M	$7.013M	$7.013M
Total Long-Term Liabilities	$422.8K	$510.2K	$510.2K
Total Liabilities	$7.081M	$7.523M	$7.523M
YoY Change	193.34%	268.29%	268.29%
SHAREHOLDERS EQUITY
Retained Earnings	-$73.41M	-$69.41M
YoY Change		34.17%
Common Stock	$1.131K	$1.131K
YoY Change		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$81.61K	$3.882M	$3.882M
YoY Change
Total Liabilities & Shareholders Equity	$7.163M	$11.41M	$11.41M
YoY Change	-61.14%	-50.17%	-50.17%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$4.005M	-$4.605M	-$17.68M
YoY Change	-19.96%	73.53%	-14.65%
Depreciation, Depletion And Amortization	$100.6K	$89.72K	$394.0K
YoY Change	-0.79%	-74.87%	-44.37%
Cash From Operating Activities	-$3.576M	-$4.206M	-$15.88M
YoY Change	-7.45%	-41.64%	52.24%
INVESTING ACTIVITIES
Capital Expenditures	$37.14K	$143.0K	$153.4K
YoY Change	-457.07%	-119.71%	-118.83%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$165.00
YoY Change
Cash From Investing Activities	-$37.14K	-$143.0K	-$152.7K
YoY Change	257.07%	-80.29%	-81.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$3.920K	-89.78K	$4.899M
YoY Change	6.52%	-100.38%	-81.54%
NET CHANGE
Cash From Operating Activities	-$3.576M	-4.206M	-$15.88M
Cash From Investing Activities	-$37.14K	-143.0K	-$152.7K
Cash From Financing Activities	-$3.920K	-89.78K	$4.899M
Net Change In Cash	-$3.618M	-4.439M	-$11.14M
YoY Change	-6.73%	-128.74%	-172.81%
FREE CASH FLOW
Cash From Operating Activities	-$3.576M	-$4.206M	-$15.88M
Capital Expenditures	$37.14K	$143.0K	$153.4K
Free Cash Flow	-$3.614M	-$4.350M	-$16.04M
YoY Change	-6.24%	-32.9%	66.73%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001862150
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments		usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax		usd
CY2021	CING	Unrealized Losses On Shortterm Investments UnrealizedLossesOnShorttermInvestments		usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
CY2022	us-gaap	Noncash Contribution Expense NoncashContributionExpense		usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities		usd
CY2021	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments		usd
CY2021	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities		usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital		usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid		usd
CY2021Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts		usd
CY2021Q4	CING	Prepaid Professional Fees PrepaidProfessionalFees		usd
CY2021Q4	CING	Prepaid Dues And Subscriptions PrepaidDuesAndSubscriptions		usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent		usd
CY2022Q4	CING	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent		usd
CY2022Q4	us-gaap	Accrued Utilities Current AccruedUtilitiesCurrent		usd
CY2021Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent		usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021Q4	CING	Deferred Tax Assets In Research And Development Costs Current DeferredTaxAssetsInResearchAndDevelopmentCostsCurrent		usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-40874
CY2022	dei	Entity Registrant Name EntityRegistrantName	Cingulate Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-3825535
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	1901 W. 47th Place
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Kansas City
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	KS
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	66205
CY2022	dei	City Area Code CityAreaCode	(913)
CY2022	dei	Local Phone Number LocalPhoneNumber	942-2300
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	11500000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	11309412	shares
CY2022	dei	Auditor Name AuditorName	KPMG LLP
CY2022	dei	Auditor Firm AuditorFirmId	185
CY2022	dei	Auditor Location AuditorLocation	Kansas City, Missouri
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5356276	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16492745	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	933	usd
CY2022Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	234432	usd
CY2021Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	690248	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2278944	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1698353	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	7869652	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	18882279	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2904787	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3145378	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	630618	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	858600	usd
CY2022Q4	us-gaap	Assets Assets	11405057	usd
CY2021Q4	us-gaap	Assets Assets	22886257	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	762357	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	264687	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	894635	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	601300	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	5000000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	16053	usd
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	15096	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	339755	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	295595	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7012800	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1176678	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	21487	usd
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	37534	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	488748	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	828503	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	510235	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	866037	usd
CY2022Q4	us-gaap	Liabilities Liabilities	7523035	usd
CY2021Q4	us-gaap	Liabilities Liabilities	2042715	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	240000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	240000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11309412	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11309412	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11309412	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11309412	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1131	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	1131	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	73289387	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	72574510	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	165	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-69408496	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-51732264	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	3882022	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	20843542	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11405057	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22886257	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8995280	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8410489	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8506438	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12268909	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-17501718	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-20679398	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-174514	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-30593	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17676232	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-20709991	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-17676232	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-20709991	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.56
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.79
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11309412	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7413579	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1292435	usd
CY2021	CING	Adjustments To Additional Paid In Capital Member Contributions AdjustmentsToAdditionalPaidInCapitalMemberContributions	7104957	usd
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4627079	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	20374218	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	43835	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	12738088	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-20709991	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	20843542	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	20843542	usd
CY2022	CING	Available For Sale Investments Value AvailableForSaleInvestmentsValue	-165	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	800796	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	85919	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-17676232	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	3882022	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	3882022	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-17676232	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-20709991	usd
CY2022	us-gaap	Depreciation Depreciation	394011	usd
CY2021	us-gaap	Depreciation Depreciation	708317	usd
CY2021	us-gaap	Noncash Contribution Expense NoncashContributionExpense	12738088	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	800796	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	43835	usd
CY2022	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	-455816	usd
CY2021	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	538476	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	580591	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1258857	usd
CY2022	CING	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-227982	usd
CY2021	CING	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-100124	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	791005	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1324686	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	44160	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	61427	usd
CY2022	CING	Increase Decrease In Longterm Portion Of Operating Lease Liability IncreaseDecreaseInLongtermPortionOfOperatingLeaseLiability	-339755	usd
CY2021	CING	Increase Decrease In Longterm Portion Of Operating Lease Liability IncreaseDecreaseInLongtermPortionOfOperatingLeaseLiability	-228938	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-23615	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15882808	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10432772	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	153420	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	814736	usd
CY2022	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	933	usd
CY2022	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	165	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-152652	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-814736	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	20374218	usd
CY2022	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	85919	usd
CY2021	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	7104957	usd
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	500335	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	5000000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	15090	usd
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	436259	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4898991	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	26542581	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-11136469	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	15295073	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	16492745	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1197672	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5356276	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	16492745	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	279730	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	19000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	114725	usd
CY2022Q3	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	5000000.0	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_844_eus-gaap--UseOfEstimates_zmkUGHVowwT3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zUnrBBAXK3mf">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during a reporting period. Actual results could differ from estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_zX9HxbhxMjRc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zYIigLPnzCQd">Concentration of Credit Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains cash equivalent deposits, which at various times throughout the fiscal year exceeded the amounts insured by the Federal Deposit Insurance Corporation limit of $<span id="xdx_903_eus-gaap--TimeDepositsAtOrAboveFDICInsuranceLimit_iI_c20221231_zd5wlxh6L3w9" title="Federal deposit insurance corporation limit">250,000</span> (without regard to reconciling items). Management monitors the soundness of these financial institutions and does not believe the Company is subject to any material credit risk relative to the uninsured portion of the deposits.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	us-gaap	Time Deposits At Or Above Fdic Insurance Limit TimeDepositsAtOrAboveFDICInsuranceLimit	250000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4964853	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4811433	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2060066	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1666055	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2904787	usd
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3145378	usd
CY2022	us-gaap	Depreciation Depreciation	394011	usd
CY2021	us-gaap	Depreciation Depreciation	708317	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-563519	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-977496	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-148393	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.00012	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y11M23D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.01126	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.01134	pure
CY2022Q4	CING	Prepaid Research And Development PrepaidResearchAndDevelopment	1377391	usd
CY2021Q4	CING	Prepaid Research And Development PrepaidResearchAndDevelopment	643917	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	472152	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	761594	usd
CY2022Q4	CING	Prepaid Active Pharmaceutical Ingredients PrepaidActivePharmaceuticalIngredients	209156	usd
CY2021Q4	CING	Prepaid Active Pharmaceutical Ingredients PrepaidActivePharmaceuticalIngredients	264361	usd
CY2022Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	100339	usd
CY2022Q4	CING	Prepaid Professional Fees PrepaidProfessionalFees	61524	usd
CY2022Q4	CING	Prepaid Dues And Subscriptions PrepaidDuesAndSubscriptions	37684	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	20698	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	28481	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2278944	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1698353	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	292339	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	314446	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	71570	usd
CY2021Q4	CING	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	250000	usd
CY2021Q4	us-gaap	Accrued Utilities Current AccruedUtilitiesCurrent	279730	usd
CY2022Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	175625	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	112225	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	894635	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	601300	usd
CY2022	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<p id="xdx_806_eus-gaap--LossContingencyDisclosures_zmnEjqdSd9Yi" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(6)</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82F_zqMz6qqjLSHj">Contingencies</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company may, from time to time, be subject to legal proceedings and claims arising in the ordinary course of business and otherwise. A substantial legal liability against us could have an adverse effect on our business, financial condition and results of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company records legal costs associated with loss contingencies as incurred and establishes reserves when those matters present material loss contingencies that management determines to be both probable and reasonably estimable in accordance with ASC 450, <i>“Contingencies.” </i>If a range of loss is estimated, and some amount within that range appears to be a better estimate than any other amount within that range, then that amount is accrued. If no amount within the range can be identified as a better estimate than any other amount, we accrue the minimum amount in the range. These amounts are not reduced by amounts that may be recovered under insurance or claims against third parties, but undiscounted receivables from insurers or other third parties may be accrued separately if recovery is considered probable. Management’s judgment is required related to loss contingencies because the outcomes are difficult to predict, and the ultimate resolution may differ from our current analysis. The Company revises accruals in light of new information. While it is not possible to predict the outcome of loss contingencies with certainty, management is of the opinion that adequate provision for potential losses associated with any such matters has been made in the financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.13
CY2022	us-gaap	Class Of Warrant Or Right Reason For Issuing To Nonemployees ClassOfWarrantOrRightReasonForIssuingToNonemployees	warrants are exercisable from December 10, 2021 through December 10, 2026.
CY2022	CING	Income Tax Reconciliation Permanent Difference IncomeTaxReconciliationPermanentDifference	11935	usd
CY2021	CING	Income Tax Reconciliation Permanent Difference IncomeTaxReconciliationPermanentDifference	44804	usd
CY2022	us-gaap	Interest Expense InterestExpense	292339	usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	240000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	240000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11309412	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11309412	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11309412	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11309412	shares
CY2021Q3	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	0.029	shares
CY2021Q3	us-gaap	Stock Dividends Shares StockDividendsShares	448045	shares
CY2022	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	On October 12, 2021, Cingulate effected a reverse stock split of its issued and outstanding shares of common stock at a ratio of 0.699-for-1, and on November 29, 2021, Cingulate effected a second reverse stock split of its issued and outstanding shares of common stock at a ratio of 0.64259-for-1 (the “Reverse Stock Splits”). No fractional shares of common stock were issued in connection with either of the Reverse Stock Splits, and all such fractional interests were rounded down to the nearest whole number. All share data, per share data and related information for all periods presented in the accompanying consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Splits.
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.01889	pure
CY2022	CING	Class Of Warrant Or Right Outstanding Underwritten Public Offering ClassOfWarrantOrRightOutstandingUnderwrittenPublicOffering	4791665	shares
CY2022	CING	Class Of Warrant Or Right Exercise Price Of Warrants Underwritten Public Offering ClassOfWarrantOrRightExercisePriceOfWarrantsUnderwrittenPublicOffering	6.00
CY2022	CING	Class Of Warrant Or Right Grant Date Fair Value Per Warrant Underwritten Public Offering ClassOfWarrantOrRightGrantDateFairValuePerWarrantUnderwrittenPublicOffering	4.77
CY2022	CING	Warrants And Rights Outstanding Grant Date Fair Value Underwritten Public Offering WarrantsAndRightsOutstandingGrantDateFairValueUnderwrittenPublicOffering	22856242	usd
CY2022	CING	Class Of Warrant Or Right Outstanding Issuanceof Underwriter Warrants ClassOfWarrantOrRightOutstandingIssuanceofUnderwriterWarrants	208333	shares
CY2022	CING	Class Of Warrant Or Right Exercise Price Of Warrants Issuanceof Underwriter Warrants ClassOfWarrantOrRightExercisePriceOfWarrantsIssuanceofUnderwriterWarrants	7.50
CY2022	CING	Class Of Warrant Or Right Grant Date Fair Value Per Warrant Issuance Of Underwriter Warrants ClassOfWarrantOrRightGrantDateFairValuePerWarrantIssuanceOfUnderwriterWarrants	4.64
CY2022	CING	Warrants And Rights Outstanding Grant Date Fair Value Issuance Of Underwriter Warrants WarrantsAndRightsOutstandingGrantDateFairValueIssuanceOfUnderwriterWarrants	966665	usd
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4999998	shares
CY2022Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	23822907	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	48822907	usd
CY2022Q4	CING	Equity Fair Value Percentage EquityFairValuePercentage	1	pure
CY2022	CING	Amount Allocated AmountAllocated	25000000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3712008	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4733324	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	713701	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-55755	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-46593	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5580595	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	847269	usd
CY2022Q4	CING	Deferred Tax Assets In Research And Development Costs Current DeferredTaxAssetsInResearchAndDevelopmentCostsCurrent	343087	usd
CY2022Q4	CING	Deferred Tax Assets Other Current DeferredTaxAssetsOtherCurrent	59018	usd
CY2021Q4	CING	Deferred Tax Assets Other Current DeferredTaxAssetsOtherCurrent	4050	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3381215	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1201974	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1762716	usd
CY2022Q4	CING	Deferred Tax Assets Unvested Stock Options Non Current DeferredTaxAssetsUnvestedStockOptionsNonCurrent	204380	usd
CY2021Q4	CING	Deferred Tax Assets Unvested Stock Options Non Current DeferredTaxAssetsUnvestedStockOptionsNonCurrent	11835	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	92417	usd
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	90480	usd
CY2022Q4	CING	Deferred Tax Assets Rightofuse Assets DeferredTaxAssetsRightofuseAssets	63563	usd
CY2021Q4	CING	Deferred Tax Assets Rightofuse Assets DeferredTaxAssetsRightofuseAssets	49606	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	5906396	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1357945	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5580595	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	847269	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	325801	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	510676	usd
CY2022Q4	CING	Deferred Tax Liabilities Accrual To Cash Current DeferredTaxLiabilitiesAccrualToCashCurrent	11228	usd
CY2021Q4	CING	Deferred Tax Liabilities Accrual To Cash Current DeferredTaxLiabilitiesAccrualToCashCurrent	105075	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	314573	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	405601	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	325801	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	510676	usd
CY2018	us-gaap	Payments For Rent PaymentsForRent	61786	usd
CY2019Q4	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	this lease was extended for a period of twenty-four months with a monthly lease payment of $37,072.
CY2019Q4	us-gaap	Payments For Rent PaymentsForRent	37072	usd
CY2022	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	In April 2020, the Company entered into a 60-month lease agreement for office furniture under a lease classified as a financing lease as title of the furniture transfers to the Company at the end of the lease term. Monthly lease payments are $1,491. The leased furniture is amortized on a straight-line basis over 7 years. The imputed interest rate relating to the lease obligation is 6.12% and the maturity date is March 2025.
CY2020Q2	us-gaap	Payments For Rent PaymentsForRent	1491	usd
CY2021	CING	Percentage Of Imputed Interest Rate Of Lease Obligation PercentageOfImputedInterestRateOfLeaseObligation	0.0612	pure
CY2021	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	26504	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	15090	usd
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	436259	usd
CY2022	CING	Operating Leases Reductions To Right Of Use Assets Lease Obligations OperatingLeasesReductionsToRightOfUseAssetsLeaseObligations	227981	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	338787	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	338787	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	10990	usd
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	409927	usd
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	2804	usd
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	26504	usd
CY2022	CING	Finance Lease Cost FinanceLeaseCost	13794	usd
CY2021	CING	Finance Lease Cost FinanceLeaseCost	436431	usd
CY2022	us-gaap	Lease Cost LeaseCost	352581	usd
CY2021	us-gaap	Lease Cost LeaseCost	775218	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	630618	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	858600	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	339755	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	295595	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	488748	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	828503	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	828503	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1124098	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	76928	usd
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	76928	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	44988	usd
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	29602	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	31940	usd
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	47326	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	16053	usd
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	15096	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	21487	usd
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	37534	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	21487	usd
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	37534	usd
CY2022Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	37540	usd
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	52630	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	36000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	433172	usd
CY2022	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	3698	usd
CY2021	CING	Operating Leases Reductions To Right Of Use Assets Lease Obligations OperatingLeasesReductionsToRightOfUseAssetsLeaseObligations	196245	usd
CY2022	CING	Finance Leases Reductions To Right Of Use Assets Lease Obligations FinanceLeasesReductionsToRightOfUseAssetsLeaseObligations	10990	usd
CY2021	CING	Finance Leases Reductions To Right Of Use Assets Lease Obligations FinanceLeasesReductionsToRightOfUseAssetsLeaseObligations	409927	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P25M
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P39M
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P27M
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P39M
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1162	pure
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1157	pure
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0612	pure
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0612	pure
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-17676232	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-20709991	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11309412	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7413579	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.56
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.79
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5861017	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5523283	shares
CY2022Q4	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	0	usd
CY2021Q4	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	0	usd
CY2022	us-gaap	Interest Expense InterestExpense	292339	usd
CY2022	CING	Accrued Interest AccruedInterest	292339	usd

Files In Submission

Name	View Source	Status
0001493152-23-007252-index-headers.html	Edgar Link	pending
0001493152-23-007252-index.html	Edgar Link	pending
0001493152-23-007252.txt	Edgar Link	pending
0001493152-23-007252-xbrl.zip	Edgar Link	pending
cing-20221231.xsd	Edgar Link	pending
ex10-10.htm	Edgar Link	pending
ex10-19.htm	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex23-1_001.jpg	Edgar Link	pending
ex24-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
cing-20221231_cal.xml	Edgar Link	unprocessable
cing-20221231_def.xml	Edgar Link	unprocessable
cing-20221231_lab.xml	Edgar Link	unprocessable
cing-20221231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
form10-k_002.jpg	Edgar Link	pending
form10-k_003.jpg	Edgar Link	pending
form10-k_004.jpg	Edgar Link	pending
form10-k_005.jpg	Edgar Link	pending
form10-k_006.jpg	Edgar Link	pending
form10-k_007.jpg	Edgar Link	pending
form10-k_008.jpg	Edgar Link	pending
form10-k_009.jpg	Edgar Link	pending
form10-k_010.jpg	Edgar Link	pending
form10-k_011.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
form10-k_htm.xml	Edgar Link	completed
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CING
Cingulate Inc Stock $cing

2023 Q1 Form 10-K Financial Statement

#000149315223007252 Filed on March 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CING Cingulate Inc Stock $cing

2023 Q1 Form 10-K Financial Statement

#000149315223007252 Filed on March 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CING
Cingulate Inc Stock $cing